STAT3 is constitutively active in some patients with Polycythemia rubra vera

被引:72
作者
Röder, S
Steimle, C
Meinhardt, G
Pahl, HL
机构
[1] Univ Hosp Freiburg, Dept Expt Anesthesiol, D-79106 Freiburg, Germany
[2] Univ Hosp Munich, Dept Hematol Oncol, Munich, Germany
关键词
D O I
10.1016/S0301-472X(01)00637-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Polycythemia vera is a clonal stem cell disorder characterized by hyperproliferation of the erythroid, myeloid, and megakaryocytic lineages, While it has been shown that progenitor cells of P. vera patients are hypersensitive to several growth factors including erythropoietin, insulin-like growth factor-1, thrombopoietin, interleukin-3, and granulocyte/monocyte colony-stimulating factor, the molecular pathogenesis of this disease remains unknown. Growth factor hypersensitivity could be mediated by changes in signal transduction pathways, We therefore investigated a common downstream effector of cytokines, the signal transducers and activators of transcription (STATs), A constitutive activation of STAT factors could explain the increased proliferation of P. vera cells even in the absence of growth factor stimulation. Methods. Peripheral granulocytes from patients with P. vera and from healthy volunteers were assayed for STAT1, 3, and 5 DNA binding by electrophoretic mobility shift assay. Results. Four of 14 P. vera patients analyzed showed constitutive STAT3 DNA binding in unstimulated peripheral granulocytes, while none of the 17 healthy volunteers tested did. None of the subjects showed constitutive STAT1 or STETS activity, Western blotting demonstrated that, in the three patients, STAT3 is constitutively phosphorylated on Tyr 705, whereas it is unphosphorylated in the other patients and in controls. Interestingly, constitutive STAT3 activity did not correlate with the duration of disease or the treatment regimen. It was observed in a recently diagnosed patient and in two patients treated only with phlebotomy. Conclusion. Our data suggest that constitutive phosphorylation and activation of STAT3 is not a secondary event induced by mutagenizing agents or by prolonged hyperproliferation of hematopoietic cells, but rather represents a primary molecular aberration. Constitutively active STAT3 may contribute to the growth factor hypersensitivity of P. vera cells. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:694 / 702
页数:9
相关论文
共 59 条
  • [1] POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE
    ADAMSON, JW
    FIALKOW, PJ
    MURPHY, S
    PRCHAL, JF
    STEINMANN, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) : 913 - 916
  • [2] Andersson P, 1997, EUR J HAEMATOL, V59, P310
  • [3] The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera
    Asimakopoulos, FA
    Hinshelwood, S
    Gilbert, JGR
    Delibrias, CC
    Gottgens, B
    Fearon, DT
    Green, AR
    [J]. ONCOGENE, 1997, 14 (10) : 1215 - 1222
  • [4] BILGRAMI S, 1995, SEMIN ONCOL, V22, P307
  • [5] Brizzi MF, 1996, J BIOL CHEM, V271, P3562
  • [6] Stat3 as an oncogene
    Bromberg, JF
    Wrzeszczynska, MH
    Devgan, G
    Zhao, YX
    Pestell, RG
    Albanese, C
    Darnell, JE
    [J]. CELL, 1999, 98 (03) : 295 - 303
  • [7] Stat3 activation is required for cellular transformation by v-src
    Bromberg, JF
    Horvath, CM
    Besser, D
    Lathem, WW
    Darnell, JE
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (05) : 2553 - 2558
  • [8] Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
    Carlesso, N
    Frank, DA
    Griffin, JD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 811 - 820
  • [9] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115
  • [10] Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010